HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Adds Good Start Brand In $230M Statement On Boosting Infant Formula Production Capacity

Executive Summary

Good Start formula line marketed in US and in Canada will move to Perrigo from Nestle along with a formula plant in Wisconsin, where Perrigo will expand current 29mil pound annual production capacity to 36m within 18 months. Good Start available in US as part of iconic Gerber brand and under Nestle brand in Canada.

You may also be interested in...



Perrigo Prepares To Pioneer US OTC Birth Control Sales As ‘Supply Chain Reinvention’ Continues

Firm reports Q2 net sales up 6.4% to $1.2bn while organic measure was 0.8% growth after a 2.7 percentage point drag from SKU prioritization moves. Investment planned over second half to prepare for launch of Opill sales.

Abbott Stops Using ‘#1 Infant Formula Brand’ Claim After Finding Supporting Data Out Of Date

Mead Johnson not only gains with Abbott stopping use of claim on Similac packaging, but also continues using similar claim on Enfamil packages, “#1 Pediatrician Recommended Brand.”  In NAD report, Abbott says data backing up its claim apparently wasn’t current.

Perrigo Pays For Growth Drivers In Q1 Results

Perrigo reports $1.2bn net sales, up 13% excluding loss to foreign exchange or 6.4% on an organic measure excluding additions to its portfolio and other operating changes since the year-ago period, but also a $3m net loss.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel